Fig. 4From: One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stagesThe total numbers of intravitreal ranibizumab injections given during 12 months of follow-up for 41 eyes with retinal angiomatous proliferation (RAP) (* P < 0.001)Back to article page